Search

Displaying results 1261 - 1270 of 6076 in total
  1. Drug

    Equine Botulinum Neurotoxin G Immune FAB2

    go.drugbank.com/drugs/DB13899
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and pediatric patients.

  2. Drug

    Equine Botulinum Neurotoxin D Immune FAB2

    go.drugbank.com/drugs/DB13902
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients.

  3. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    Ebola virus (EBOV) remains an important human pathogen within the _Ebolavirus_ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. … [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.

    Categories: Treatments for Ebola Virus Disease
  4. Drug

    Lindane

    go.drugbank.com/drugs/DB00431
    ApprovedWithdrawn

    Lindane is still allowed for pharmaceutical use until 2015. … In Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical

  5. Drug

    Vonoprazan

    go.drugbank.com/drugs/DB11739
    ApprovedInvestigational

    PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. … [A253702] In May 2022, the FDA approved the use of vonoprazan in a co-packaged product containing amoxicillin and clarithromycin for the treatment of _H. pylori_ infection.

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  6. Drug

    Islatravir

    go.drugbank.com/drugs/DB15653
    ApprovedInvestigational

    Islatravir is a first-in-class, highly potent nucleoside reverse transcriptase translocation inhibitor (NRTTI) used in combination therapy for the treatment of HIV-1 infection. … [L56141] This formulation represents a significant advance in long-acting oral therapy due to islatravir's exceptionally long intracellular half-life, which allows for extremely low dosing.

  7. Drug

    Narsoplimab

    go.drugbank.com/drugs/DB16418
    ApprovedInvestigational

    [A241030] Evidence increasingly points to a role for the complement system in TMA. … [A241030, A241040] Narsoplimab (OMS721), a human IgG4λ anti-MASP-2 antibody, is under consideration as a treatment for hematopoietic stem cell transplant-associated TMA (HSCT-TMA/TA-TMA) and IgA nephropathy

  8. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    novel in that it is the first and only oral CGRP antagonist approved for preventative use in migraine. … [L44642] It also received approval for preventive treatment of adult migraine by the EMA in August 2023.

  9. Drug

    Phenylpropanolamine

    go.drugbank.com/drugs/DB00397
    ApprovedVet approvedWithdrawn

    Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.

    Categories: Nasal Decongestants for Systemic Use, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  10. Drug

    Esketamine

    go.drugbank.com/drugs/DB11823
    ApprovedInvestigational

    The intranasal route of administration for this drug allows for easy administration and a fast onset of action, which sets it apart from many other antidepressant agents that may take several weeks to … This is the first time that the FDA has approved esketamine for any use. The FDA approved ketamine (Ketalar) in 1970.

    Categories: Antidepressive Agents Indicated for Depression